Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here is one stock where Wall Street’s positive outlook is supported by strong fundamentals and two where consensus estimates seem disconnected from reality.
Two Stocks to Sell:
The Real Brokerage (REAX)
Consensus Price Target: $29.90 (92.1% implied return)
Founded in Toronto, Canada in 2014, The Real Brokerage (NASDAQ: REAX) is a technology-driven real estate brokerage firm combining a tech-centric model with an agent-centric philosophy.
Why Does REAX Fall Short?
- Responsiveness to unforeseen market trends is restricted due to its substandard operating margin profitability
- Low free cash flow margin of 3.8% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
At $15.56 per share, The Real Brokerage trades at 1.2x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than REAX.
Lemonade (LMND)
Consensus Price Target: $59.22 (30.5% implied return)
Built on the principle of giving back unused premiums to charitable causes selected by policyholders, Lemonade (NYSE: LMND) is a technology-driven insurance company that offers homeowners, renters, pet, car, and life insurance through an AI-powered digital platform.
Why Do We Think Twice About LMND?
- Annual earnings per share growth of 8% underperformed its revenue over the last five years, showing its incremental sales were less profitable
- Products and services are facing significant credit quality challenges during this cycle as book value per share has declined by 18.4% annually over the last five years
- Negative return on equity shows management lost money while trying to expand the business
Lemonade’s stock price of $45.38 implies a valuation ratio of 7.1x forward P/B. To fully understand why you should be careful with LMND, check out our full research report (it’s free).
One Stock to Watch:
Celsius (CELH)
Consensus Price Target: $42.29 (48.9% implied return)
With its proprietary MetaPlus formula as the basis for key products, Celsius (NASDAQ: CELH) offers energy drinks that feature natural ingredients to help in fitness and weight management.
Why Do We Like CELH?
- Annual revenue growth of 47.4% over the last three years was superb and indicates its market share is rising
- Earnings per share grew by 91.4% annually over the last three years and trumped its peers
- CELH is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders, and its improved cash conversion implies it’s becoming a less capital-intensive business
Celsius is trading at $28.41 per share, or 19.4x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
